Global Roxatidine Market Size, Share and Trends Analysis Report, By Formulation (Oral, Injectable), By Application (Acidity, Heartburn, Intestinal Ulcers, Stomach Ulcers, Others), Forecast (2022-2028)

The global roxatidine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Roxatidine is a special H2-receptor antagonist, highly targeted for reflux esophagitis, benign gastric ulcer, duodenal ulcer, and prophylaxis of recurrent ulcers. The roxatidine market is growing at a steady rate and with the increasing adoption of strategies by key players, the market is expected to increase over the forecasted period. Compared to other H2 receptor antagonists, Roxatidine contains a higher selectivity of H2 receptors and has a strong effect on acid stress. In addition, it contains a protective mucosal effect that other H2 receptors lack. Although Roxatidine has similar therapeutic potential to Proton pump inhibitors, it is safer, more stable, and more expensive. These outstanding benefits are evidence of the clinical significance of Roxatidine. Roxatidine becomes the first drug used for gastrointestinal bleeding in overseas markets.

The increase in the number of people suffering from ulcers, the lower the cost of the drug, and its ability to reduce stomach acid production is expected to increase the need for the drug. However, certain side effects of the drug such as chest pain, weakness, elevated lipid levels in the blood, and gastrointestinal disturbances the market growth. For instance, in 2019, Boryung Pharmaceutical’s Stogar dominates the lafutidine market. U-BIST data has shown that Stogar’s annual orders recorded $ 13.9 billion, with competing drugs shipping less than $ 2 billion in sales each year.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Formulation
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- A S Joshi & Co., Sanofi, Sihuan Pharmaceutical Holding Group Ltd., Sun Pharmaceuticals Industries Ltd., and Taj Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Roxatidine Market Report by Segment

By Formulation

• Oral
• Injectable

By Application

• Acidity
• Heartburn
• Intestinal Ulcers
• Stomach Ulcers
• Others

Global Roxatidine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa